These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Antitoxin Use in the Prevention and Treatment of Anthrax Disease: A Systematic Review. Hesse EM; Godfred-Cato S; Bower WA Clin Infect Dis; 2022 Oct; 75(Suppl 3):S432-S440. PubMed ID: 36251559 [TBL] [Abstract][Full Text] [Related]
12. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax. Tierney BC; Martin SW; Franzke LH; Marano N; Reissman DB; Louchart RD; Goff JA; Rosenstein NE; Sever JL; McNeil MM; Clin Infect Dis; 2003 Oct; 37(7):905-11. PubMed ID: 13130401 [TBL] [Abstract][Full Text] [Related]
15. Anthrax. From bioweapons backwater to main attraction. Bohannon J Science; 2003 Apr; 300(5618):414-5. PubMed ID: 12702854 [No Abstract] [Full Text] [Related]
16. Antitoxin Treatment of Inhalation Anthrax: A Systematic Review. Huang E; Pillai SK; Bower WA; Hendricks KA; Guarnizo JT; Hoyle JD; Gorman SE; Boyer AE; Quinn CP; Meaney-Delman D Health Secur; 2015; 13(6):365-77. PubMed ID: 26690378 [TBL] [Abstract][Full Text] [Related]
17. From the Centers for Disease Control and Prevention. Additional options for preventive treatment for exposed persons to inhalational anthrax. JAMA; 2002 Feb; 287(5):579. PubMed ID: 11838446 [No Abstract] [Full Text] [Related]
18. BioThrax and Anthrasil for anthrax. Med Lett Drugs Ther; 2016 May; 58(1494):62. PubMed ID: 27148924 [No Abstract] [Full Text] [Related]
19. A Review of the Efficacy of FDA-Approved Couse Z; Cui X; Li Y; Moayeri M; Leppla S; Eichacker PQ Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33450877 [TBL] [Abstract][Full Text] [Related]